Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 35 h ago

Nurix Therapeutics, Inc.: PERCEPTIVE ADVISORS LLC amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Perceptive Advisors LLC amended its Schedule 13G filing on Nurix Therapeutics, Inc., updating its beneficial ownership stake with the SEC under accession number 0001193125-26-463812. The amendment signals a change in the institutional investor's position in the clinical-stage biopharmaceutical company. Schedule 13G filings are required of investors holding more than 5% of a company's shares, making the update a notable indicator of shifting institutional sentiment. Investors will watch for the specific ownership percentage disclosed and any subsequent 13G or 13D filings that clarify whether Perceptive's stake increased or decreased.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Nurix Therapeutics, Inc., Perceptive Advisors LLC